Incendia Therapeutics
Clinical-stage biotechnology company focused on discovery and development of monoclonal antibody therapies that modulate the tumor microenvironment to enable immune cell infiltration of solid tumors. The company conducts early-phase clinical trials, translational biomarker research, and computational pathology collaborations to support clinical development decisions.
Industries
Nr. of Employees
small (1-50)
Incendia Therapeutics
Products
PRTH-101 (DDR1-targeting monoclonal antibody)
A humanized monoclonal antibody that binds the extracellular domain of discoidin domain receptor 1 (DDR1) and blocks its interaction with collagen to disrupt tumor-associated collagen alignment and potentially enable T-cell infiltration.
Aurora™ 3D Spatial Biology Platform
A platform that stains, chemically clarifies, images, and analyzes entire, intact tissue samples for 3D spatial biology analysis, including tumor, immune cell, and collagen features in the tumor microenvironment.
3D I/O Pro™
A novel assay for 3D spatial quantification of lymphocyte infiltration and collagen features in the tumor microenvironment.
Ens-L1-SVM model
A machine learning model trained to classify CD8-based immune phenotypes using features extracted from H&E images alone, predicting immune exclusion and infiltration in tumor microenvironments.
PRTH-101 (DDR1-targeting monoclonal antibody)
A humanized monoclonal antibody that binds the extracellular domain of discoidin domain receptor 1 (DDR1) and blocks its interaction with collagen to disrupt tumor-associated collagen alignment and potentially enable T-cell infiltration.
Aurora™ 3D Spatial Biology Platform
A platform that stains, chemically clarifies, images, and analyzes entire, intact tissue samples for 3D spatial biology analysis, including tumor, immune cell, and collagen features in the tumor microenvironment.
3D I/O Pro™
A novel assay for 3D spatial quantification of lymphocyte infiltration and collagen features in the tumor microenvironment.
Ens-L1-SVM model
A machine learning model trained to classify CD8-based immune phenotypes using features extracted from H&E images alone, predicting immune exclusion and infiltration in tumor microenvironments.
Services
Conduct of preclinical-to-clinical development activities, early-phase trial execution, dose selection and combination evaluations with PD-1 inhibitors.
Development and validation of image-based and spatial transcriptomic biomarkers to characterize immune exclusion and stratify patients for therapies targeting the tumor microenvironment.
Conduct of preclinical-to-clinical development activities, early-phase trial execution, dose selection and combination evaluations with PD-1 inhibitors.
Development and validation of image-based and spatial transcriptomic biomarkers to characterize immune exclusion and stratify patients for therapies targeting the tumor microenvironment.
Expertise Areas
- Clinical trial management (early-phase and registrational planning)
- Monoclonal antibody discovery and development
- Tumor microenvironment research
- Biomarker discovery and validation
Key Technologies
- Spatial transcriptomics
- Multiplex immunofluorescence (mIF)
- H&E whole-slide image analysis
- Machine learning for pathology (Ens-L1-SVM and similar models)
News & Updates
Appointment of a CFO with prior healthcare finance experience; will oversee equity financing, investor relations, business development, FP&A and accounting.
Board expansion with appointment of a biotechnology investor and entrepreneur.
Enrollment of first patient in Phase 1c study evaluating PRTH-101 alone or with a PD-1 inhibitor; Phase 1 data informed recommended Phase 2 dose.
Presented clinical results in thymic epithelial carcinoma, reported median PFS and partial responses; announced plan for pivotal Phase 2 trial comparing antibody plus PD-1 inhibitor to PD-1 inhibitor alone.
Presented data on DDR1 expression, spatial transcriptomics, H&E-derived immune phenotypes, and imaging-based collagen features across multiple conferences.
Peer-reviewed article reporting preclinical evidence that DDR1 blockade disrupts collagen alignment and reverses immune exclusion.
Appointment of a CFO with prior healthcare finance experience; will oversee equity financing, investor relations, business development, FP&A and accounting.
Board expansion with appointment of a biotechnology investor and entrepreneur.
Enrollment of first patient in Phase 1c study evaluating PRTH-101 alone or with a PD-1 inhibitor; Phase 1 data informed recommended Phase 2 dose.
Presented clinical results in thymic epithelial carcinoma, reported median PFS and partial responses; announced plan for pivotal Phase 2 trial comparing antibody plus PD-1 inhibitor to PD-1 inhibitor alone.
Presented data on DDR1 expression, spatial transcriptomics, H&E-derived immune phenotypes, and imaging-based collagen features across multiple conferences.
Peer-reviewed article reporting preclinical evidence that DDR1 blockade disrupts collagen alignment and reverses immune exclusion.